Skip to content

Catalyst Pharmaceutical CPRX Net Investment in Lease

Net Investment in Lease at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
Scholar Rock logo
Scholar RockSRRK
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM

Other financials

Income statement

See full
Revenue$149.4M+5.6%
Gross profit$134.9M+9.2%
Operating income$73.2M+15.6%
Net income$63.7M+12.3%
EPS (diluted)$0.50+11.1%

Balance sheet

See full
Cash & equivalents$755.9M+30.2%
Total debt$2.7M-13.3%
Total equity$1.0B+27.5%
Total assets$1.1B+26.3%

Cash flow

See full
Operating cash flow$59.6M-0.8%
CapEx$27.0K
Free cash flow$59.6M-0.8%

Valuation

See full
Market cap$3.84B+2.7%
Enterprise value$3.09B-4.1%
P/E17.4×-1.6×
P/S6.4×-0.6×

Profitability

See full
Gross margin86%-0.2pp
Operating margin44.8%+1.6pp
Net margin37.1%+0.2pp
FCF margin34.9%-15.2pp

Returns & leverage

See full
Return on equity24.5%-4.6pp
Debt / equity0.0×
Current ratio7.1×+1.0×

Where this comes from

Reported directly by Catalyst Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Catalyst Pharmaceutical's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Catalyst Pharmaceutical's net investment in lease?
Catalyst Pharmaceutical (CPRX) reported net investment in lease of $1.86M in Q1 2026.
How has Catalyst Pharmaceutical's net investment in lease changed year-over-year?
Catalyst Pharmaceutical's net investment in lease decreased by 13.9% year-over-year, from $2.16M to $1.86M.